This inventor holds 1 USPTO granted patent. Top assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Michal Obercyger: Innovator in Metabolic Syndrome Treatments
Introduction
Michal Obercyger is a notable inventor based in Ramat Gan, Israel. He has made significant contributions to the field of medical research, particularly in the treatment of diseases associated with metabolic syndrome. His innovative approach combines bile acids with amino acids to create effective therapeutic solutions.
Latest Patents
Obercyger holds a patent for "Bile acid-basic amino acid conjugates and uses thereof." This patent focuses on compositions and methods for treating diseases or disorders related to metabolic syndrome. The invention involves conjugates of bile acids with basic amino acids or decarboxylated amino acids, such as agmatine. Specifically, it includes bile acid-basic amino acid conjugates that feature chenodeoxycholic acid combined with amino acids like arginine, lysine, histidine, and ornithine.
Career Highlights
Obercyger is affiliated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work at this esteemed institution has allowed him to explore innovative solutions to complex health issues. His research has the potential to impact the treatment landscape for metabolic syndrome significantly.
Collaborations
Throughout his career, Michal Obercyger has collaborated with esteemed colleagues, including Oren Tirosh and Ira Voloshin. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic methods.
Conclusion
In summary, Michal Obercyger is a pioneering inventor whose work in bile acid-basic amino acid conjugates offers promising avenues for treating metabolic syndrome. His contributions to medical research are noteworthy and reflect his commitment to advancing healthcare solutions.